Skip to main content
. 2020 Jun 22;20:578. doi: 10.1186/s12885-020-07041-7

Table 2.

Chemotherapy related toxicities according to CTCAE (Grade I/II) comparing cycles of mSTF (n = 56) with cycles of NC (n = 62)

NC mSTF PE ± SD* 95% CI P-Value
Infection 2 (3.4%) 4 (7.3%) 0.07 ± 0.04 0.01–0.15 0.097
Fatigue 22 (37.9%) 25 (45.5%) -0.01 ± 0.09 − 0.20 – 0.17 0.882
Insomnia 2 (3.4%) 4 (7.3%) 0.03 ± 0.04 − 0.05 – 0.11 0.505
Headachesa 2 (5.7%) 0 −0.03 ± 0.06 − 0.14 – 0.09 0.649
Dizzinessa 3 (8.6%) 2 (7.1%) −0.10 ± 0.07 −0.25 – 0.05 0.187
Depression 2 (3.4%) 2 (3.6%) − 0.02 ± 0.04 − 0.10 – 0.06 0.560
Nausea 22 (37.9%) 16 (29.1%) − 0.01 ± 0.10 −0.21 – 0.18 0.895
Vomiting 0 2 (3.6%) 0.02 ± 0.03 −0.03 – 0.08 0.413
Diarrhea 2 (3.4%) 2 (3.6%) −0.01 ± 0.04 −0.09 – 0.07 0.877
Obstipationb 5 (8.8%) 4 (7.3%) −0.02 ± 0.06 −0.13 – 0.09 0.688
Stomach painsa 1 (2.9%) 0 −0.02 ± 0.04 −0.10 – 0.07 0.695
Reduced appetitea 7 (20.0%) 2 (7.1%) −0.16 ± 0.11 −0.39 – 0.06 0.150
Hungerc 2 (5.6%) 0 −0.03 ± 0.06 −0.15 – 0.09 0.606
Stomatitis 15 (25.9%) 3 (5.5%) −0.16 ± 0.06 −0.28 – (− 0.03) 0.013
Esophagitis 2 (3.4%) 2 (3.6%) 0.01 ± 0.04 − 0.08 – 0.09 0.892
Neuroses 8 (13.8%) 10 (18.2%) 0.07 ± 0.07 −0.06 – 0.20 0.280
Arthralgia 1 (1.7%) 2 (3.6%) 0.02 ± 0.03 −0.05 – 0.09 0.614
Pain 11 (19%) 3 (5.5%) − 0.11 ± 0.06 −0.23 – 0.01 0.075
Dyspnea 0 2 (3.6%) 0.03 ± 0.02 − 0.01 – 0.07 0.098
Oedemas 0 1 (1.8%) 0.0 ± 0.02 −0.04 – 0.04 0.840

Values are shown as mean ± SD. Due to missing data, we included data of 58 cycles of NC and 55 cycles of mSTF in this analysis.*PE ± SD represents the difference for CTCAE points between cycles of NC and those of mSTF. All side effects were scored according to CTCAE v.4.0. Each side effect was scored once per patient during each chemotherapy cycle. a n = 63; b n = 112; c n = 64